UpFrontPSMA: a randomized phase 2 study of sequential 177Lu‐PSMA‐617 and docetaxel vs docetaxel in metastatic hormone‐naïve prostate cancer (clinical trial protocol)
Abstract
To assess the activity and safety of sequential lutetium‐177 (177Lu)‐PSMA‐617 and docetaxel vs docetaxel on a background of androgen deprivation therapy (ADT) in men with de novo metastatic hormone‐naïve prostate cancer (mHNPC).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 21, 2021
- Source ID
- 10.1111/bju.15384
Entities
People
- Anthony M Joshua
- Arun Azad
- David A. Pattison
- Declan G Murphy
- Ian D. Davis
- Ian Vela
- Louise Emmett
- Mathias Bressel
- Michael S Hofman
- Nattakorn Dhiantravan
- Nitika Neha
- Roslyn J. Francis
- Scott M Williams
- Shahneen K Sandhu
Organizations
- Garvan Institute of Medical Research
- Monash University
- Movember Foundation
- Peter MacCallum Cancer Centre
- Princess Alexandra Hospital, Brisbane
- Queensland University of Technology
- Sir Charles Gairdner Hospital
- St Vincent's Hospital
- United States Department of Defense
- University of Melbourne
- University of Queensland
- University of Western Australia